How Far Could ISRG Stock Bounce From Here?

Intuitive Surgical (ISRG) stock could climb 23.9% to the April high it last fell back from, and you would risk about 5% to find out. That looks like a surgical-robot leader on sale, but the price history disagrees. Over the last two years, none of its visits to this price range turned into a 20% gain before a 5% drop.

Where Does The Upside Stop?

At $393.33, the stock sits where buyers have stepped in before. The upside case is a move back to $487.45, the high it last fell from in April. First it has to clear two smaller stall points, at $429.72 and $452.35.

The downside line is $373.66, 5% below today’s price. A drop below that level would break the technical support zone that buyers have previously defended. So you are weighing about 24% up against 5% down, roughly 4.8 to 1, though the first stall point is only 9.3% away. The ratio is no forecast of which way the stock goes.

Why Have Buyers At This Price Been Let Down Before?

Before the last two years, the stock bounced from this price range three times, all in the first half of 2024. Two stalled after gains of about 9% to 10%, which from today would barely reach the first stall point. Only one beat the 23.9% the target asks for: a bounce that began in May 2024 and ran 51.8% by January 2025.

Over the last two years the stock came into this range four times, and none produced a 20% gain before a 5% drop: three fell 5% first, and one has not resolved either way.

US da Vinci procedure growth slowed to 12% in the second quarter of 2026, from 14% in the first quarter, mostly in procedures patients can put off. Some customers told management that coverage changes may be affecting when patients seek care. The CEO also sees a bit of the law of large numbers at work.

The price is the other worry. From the first half of 2027, an extended use program lets some instruments be used more times, lowering what customers pay per procedure in a set of benign procedures. Management expects that to widen adoption, notes the shift toward da Vinci 5 has been accretive to revenue per procedure, and will put a number on the pricing at its next earnings call. At 44.4 times earnings, against an S&P 500 median of 22.4, the stock is priced for growth that a lower price per procedure could dent.

What Factors Would Need to Rebound for a 23.9% Recovery?

Hospitals are still buying. The company placed 468 da Vinci systems in the second quarter of 2026, up 18% from a year earlier, though about half of the US placements were trade-ins by upgrading customers. Revenue grew 20.7% over the last twelve months, against an S&P 500 median of 8.3%. The CEO argues deferred conditions usually progress and will still need treatment.

So the 23.9% is within reach only if the US slowdown is patients delaying care rather than a maturing market. Watch whether US da Vinci procedure growth climbs back toward the 14% it ran at in the first quarter, and how deep the extended use pricing cuts. Until then, historical price action alone suggests caution at these levels. Our dip-buying screen shows which fallen stocks still have the fundamentals to recover.

How Much Damage Could One Position Do To Your Net Worth?

Most portfolios hold a position that has quietly grown larger than anyone planned. Concentration tends to arrive by accident rather than by decision. What your largest position would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.